THERAPY DOSSIER · th-9c3b1303812e

HC030031 topical gel

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Burn
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31982303 ↗2020Reported benefit

Topical transient receptor potential ankyrin 1 antagonist treatment attenuates nociception and inflammation in an ultraviolet B radiation-induced burn model in mice.

MouseBurnUnspecifiedMaleTopical (cutaneous)0.05 per cent gel formulationApplied immediately after irradiation

Model: Ultraviolet B irradiation (0.75 J/cm2) of the right hind paw producing a sunburn-type cutaneous burn

HC030031 0.05 per cent reversed ultraviolet B-induced mechanical and cold allodynia (maximum inhibition 69 +/- 13 per cent and 100 per cent on day 4), reduced paw oedema (77 +/- 6 per cent on day 5) and myeloperoxidase activity (69 +/- 28 per cent), and reduced irradiation-induced calcium influx.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…